StreetInsider.com News Articles

Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma

Fri, 23 Oct 2026 10:15:00 -0400

62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis

Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up

Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Reinforces Ongoing TILVANCE-301 Phase 3 Trial

PHILADELPHIA and MADRID, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that one-time lifileucel combined with pembrolizumab

Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma

Fri, 23 Oct 2026 10:15:00 -0400

62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis

Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up

Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Reinforces Ongoing TILVANCE-301 Phase 3 Trial

Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026

Mon, 19 Oct 2026 07:00:00 -0400

Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment

Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously Treated Soft Tissue Sarcomas

PHILADELPHIA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, will present five abstracts from its TIL platform at the European Society for Medical Oncology (ESMO) Congress 2026, including two oral presentations of new clinical data

Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026

Mon, 19 Oct 2026 07:00:00 -0400

Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment

Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously Treated Soft Tissue Sarcomas

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Fri, 16 Oct 2026 17:15:00 -0400

PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 111,615 shares of Iovance’s common stock to twenty-one new, non-executive employees.

The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Fri, 16 Oct 2026 17:15:00 -0400

The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by

Iovanace Biotherapeutics (IOVA) PT Raised to $18 at Barclays

Tue, 13 Oct 2026 03:35:34 -0400

Barclays analyst Peter Lawson raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $18.00 (from $15.00) while maintaining a Overweight rating.

Iovanace Biotherapeutics (IOVA) PT Raised to $11 at Baird

Thu, 08 Oct 2026 07:24:17 -0400

Baird analyst Colleen Kusy raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $11.00 (from $6.00) while maintaining a Neutral rating.

Form 8-K IOVANCE BIOTHERAPEUTICS, For: Oct 05

Mon, 05 Oct 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20261005/27149707.html

Form 4 IOVANCE BIOTHERAPEUTICS, For: Sep 30 Filed by: Berkowitz Noah

Fri, 02 Oct 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20261002/27143333.html

Form 3 IOVANCE BIOTHERAPEUTICS, For: Sep 30 Filed by: Berkowitz Noah

Fri, 02 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261002/27143297.html

Iovance names Noah Berkowitz as chief medical officer

Thu, 01 Oct 2026 07:00:39 -0400

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has appointed Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, effective September 30, 2026, according to a company statement.

Berkowitz previously served as Chief Medical Officer at Arvinas Pharmaceuticals, where he led the clinical strategy that resulted in the first FDA approval of a targeted protein degradation therapy. Before that, he was Senior Vice President and Therapeutic Area Head, Hematology at Bristol Myers Squibb, where his teams achieved regulatory approvals for the CAR T cell therapies Abecma and Breyanzi. Clinical programs under his leadership contributed to annual sales of Reblozyl exceeding $2 billion. He also held

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Thu, 01 Oct 2026 07:00:00 -0400

Leader in Global Drug Development of T Cell Therapies

PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026.

“We are pleased to welcome Noah to Iovance as we prepare for important development and regulatory milestones for our TIL platform across multiple solid tumor cancers,” said Frederick Vogt, Ph.D., J.D., Interim President and Chief

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Thu, 01 Oct 2026 07:00:00 -0400

Leader in Global Drug Development of T Cell Therapies

Iovanace Biotherapeutics (IOVA) PT Raised to $18 at Wells Fargo

Wed, 30 Sep 2026 06:09:30 -0400

Wells Fargo analyst Nick Abbott raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $18.00 (from $14.00) while maintaining a Overweight rating.

The analyst comments "Following today's updated guidance and management discussion, we note IOVA's confidence in Amtagvi's 2H26 trajectory & 2027 growth. We also had positive takeaways on the competitive dynamics surrounding RP1's launch & the upcoming NSCLC data readout. IOVA today today raised its full year 2026 total revenue guidance from prior $350– $370MM to $410–$420MM, representing an increase of $55MM, or ~15%, at the midpoint, with the increase driven by strong U.S. demand for Amtagvi and Proleukin.

Iovanace Biotherapeutics (IOVA) PT Raised to $18 at Wells Fargo

Wed, 30 Sep 2026 06:09:30 -0400

Wells Fargo analyst Nick Abbott raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $18.00 (from $14.00) while maintaining a Overweight rating.

High-Stakes October has these Biotechs Entering Crucial Stretch

Tue, 29 Sep 2026 12:12:58 -0400

DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotechnology market is heading into a catalyst-heavy stretch, with Iovance Biotherapeutics (NASDAQ:IOVA), NeOnc Technologies Holdings (NASDAQ:NTHI), and Summit Therapeutics (NASDAQ:SMMT), moving from promises and pipelines toward events that could materially reshape how investors view their businesses.